An innovative test to detect prostate cancer by urine samples

US researchers have found an innovative test to detect prostate cancer by urine samples, depending on accurate biomed indicators that can reduce the need for painful and expensive traditional biopsies, which significantly changes the method of diagnosing the disease. In a study published by the “Ebiomedicine” magazine, the researchers analyzed urine samples from prostate cancer before and after their eradication operations, as well as samples of healthy volunteers. The researchers managed to identify 3 major important indicators: “TTC3”, “H4C5” and “Epcam”, and these indicators clearly appeared in patient samples before the operation, while they decreased significantly, or disappeared after the prostate was removed, confirming that the source of the prostate tissue was itself. Vital indicators The TTC3 protein is associated with the cell division process, and is determined by the indisputable division, which is an important mechanism that allows cells to produce new cells with different properties, contributing to cellular diversity and the revival of tissues in natural conditions. However, this process can be used abnormally in the case of cancer, which becomes a way of non -controlled reproduction. The high levels of “TTC3” protein in urine samples taken from prostate cancer patients indicate the presence of abnormal activity in the cell life cycle, making it a strong indication of the presence of the crop. The H4C5 protein is one of the most important components of the protein group known as the Eesthols, which controls how the DNA turns into the cell nucleus. The role of this protein is directly associated with the structure of chromatin, which is the complex of DNA and protein. Any changes in the regulation of chromatin lead to the effect on the genes that are activated or stopped, and thus represent an important factor in the control of the cell behavior. In the case of cancer, the imbalance in the operation of hydroes leads to disruption of this system, so that cancer cells begin to stimulate genes that help them to grow and resist quickly, and for this, this protein is an important indication of the presence of cancer disorder in the cell. Epcam is one of the most prominent molecules associated with human cancers, which is protein of the cell attachment, and is abundant on the surfaces of the epithelial cells that cover the organs and tissues. Its natural role is to help cell cohesion and regulate their growth, but studies have shown that the levels of this protein in many crops, including prostate cancer, rise. Not only is it an indication of the presence of the crop, but also participates in the capacity of cancer cells to separate from their original location, and move to other places in the body, which is the process known as the formation of metastases, and then the Epcam protein represents not only an important sign of the disease, but an active element in the development and distribution. High accuracy and prove the test high resolution; In development experiments and the next phase of verification, the distinction between the presence of cancer and the lack thereof was a very accurate percentage; It could get to know the right presence of the disease with a 91%rate. On the other hand, he managed to exclude healthy people with 84%, with the arrival of the area under the statistical evaluation curve up to 0.92%, which is a number close to the perfection, and the test showed a higher capacity than the index known as “PCA3” in the distinction between prostate cancer, and benevolent prostate engraving. The data also reported that the three important indicators retained their accuracy, even in difficult cases in which ‘PCA’ protein in the blood did not appear at high levels, as it was 78.6% in initial studies and was 85.7% in verification studies, as it was 0.89% in the distinction between cancer and benign diseases such as prostate or benign. Prostate cancer is one of the most prominent causes of death among men in the world, and it is often discovered by a blood test to measure the level of ‘PCA’ protein, but this investigation is not permanently accurate because it can lead to an unnecessary recommendation to take biopsies, which can cause small surgical procedures, but it may not have an improper treatment. The lead author of the study, Ranjan Pereira, director of the RNA Research Center at Johns Hopkins Hospital for American children, and a professor of oncology and neurosurgery at Jones Hopkins University, said that this new test provides a not -surgical and sensitive method to improve the illness and improve the diagnosis, especially in patients who have the results of the results. Arsenal will be. Accurate statistical methods to compare the results. Radiotherapy or accurate monitoring to follow cancer. With the beginning of urination. on the strongest 3, and the results showed that the genetic expression of these indicators was much higher in urine samples than cancer patients compared to healthy people, and took off to the prostate extinction, and a majority on the traditional indexes. is in favor of patients around the world. To be ready for use in laboratories.